{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:44:05Z","timestamp":1792806245415,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ygyno.2026.09.002","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:06:40Z","timestamp":1790010400000},"page":"68-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A phase II study in newly diagnosed stage III\/IV epithelial ovarian cancer evaluating carboplatin\/taxol\/pembrolizumab in patients receiving neoadjuvant chemotherapy followed by pembrolizumab maintenance with or without olaparib"],"prefix":"10.1016","volume":"213","author":[{"given":"Carson C.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati A.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn G.","family":"Dinkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Ketch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna B.","family":"Wilbanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn L.","family":"Schlenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warner K.","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Charles A.","family":"Leath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Toboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Arend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa K.L.","family":"Boitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ygyno.2026.09.002_bb0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.23434","article-title":"Case volume and neoadjuvant chemotherapy in advanced ovarian cancer","volume":"8","author":"Abel","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"10","key":"10.1016\/j.ygyno.2026.09.002_bb0010","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.09.002_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.002_bb0020","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials","volume":"115","author":"Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2026.09.002_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2026.103094","article-title":"Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: a meta-analysis of randomized trials","volume":"144","author":"Vida","year":"2026","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.002_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-58440-y","article-title":"Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial","volume":"16","author":"Aronson","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.002_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-46999-x","article-title":"Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial","volume":"15","author":"Ray-Coquard","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2026.09.002_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2025.04.504","article-title":"Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA nonmutated epithelial ovarian cancer: results from the randomized phase III ENGOT-OV43\/GOG-3036\/KEYLYNK-001 study","volume":"200","author":"Powell","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.09.002_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.002_bb0050","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.002_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2015.82","article-title":"Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90","volume":"35","author":"Zunino","year":"2016","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ygyno.2026.09.002_bb0060","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-022-13025-7","article-title":"PD-1 blockade combined with heated intraperitoneal chemotherapy improves outcome in experimental peritoneal metastases from colonic origin in a murine model","volume":"30","author":"Geva","year":"2023","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.002_bb0065","article-title":"Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial - PubMed","volume":"15","author":"R-C","year":"2024","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.ygyno.2026.09.002_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2026.09.002_bb0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:13:26Z","timestamp":1792804406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826021256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":15,"alternative-id":["S0090825826021256"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.09.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study in newly diagnosed stage III\/IV epithelial ovarian cancer evaluating carboplatin\/taxol\/pembrolizumab in patients receiving neoadjuvant chemotherapy followed by pembrolizumab maintenance with or without olaparib","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}